21022008 LifeCycle Pharma launches its first product in the U.S.

Company Announcement No. 4/2008
To: OMX Nordic Exchange Copenhagen 		Hørsholm, Denmark, February 21, 2008


 LifeCycle Pharma launches its first product in the U.S.
It will be marketed under the brand name Fenoglide™ by Sciele Pharma, Inc.

Hørsholm, Denmark, February 21, 2008; LifeCycle Pharma A/S (OMX: LCP), an
emerging specialty pharmaceutical company, announced today that its first
product, the cholesterol lowering Fenoglide™ (formerly LCP-FenoChol) for the
treatment of hyperlipidemia and hypertriglyceridemia, was launched today under
the name Fenoglide as approved by the U.S. Food and Drug Administration (FDA). 
Fenoglide will be marketed by its partner Sciele Pharma Inc. 

Fenoglide will be the lowest dose of fenofibrate available for patients.
Fenoglide will be offered in 40 mg and 120 mg strength tablets. Fenoglide
utilizes LCP's unique MeltDose® technology, a clinically validated
reformulation technology, designed to provide enhanced absorption and greater
bioavailability of the drug. 

Fenoglide will be marketed by Sciele Pharma's more than 400 sales
representatives across its diabetes and cardiovascular sales force teams. 

“Fenoglide is our first marketed product and we are extremely pleased to launch
it in the United States - and proud to be one of the very few Danish specialty
pharmaceuticals companies to take a product to the U.S. primary care market,”
said Dr. Flemming Ørnskov, President and Chief Executive Officer of LCP. “It is
a significant step forward in our strategy of becoming a fully integrated
specialty pharmaceuticals company. Sciele Pharma has a proven track record in
the cardiovascular market and we are excited about our collaboration with
them.” 
 
According to the American Heart Association (AHA), over 140 million American
adults have excessive total blood cholesterol values. Sales of fenofibrate have
increased significantly in the last few years, and in 2006, fenofibrate sales
totaled USD 1.7 billion worldwide, an increase of 16% over 2005. In the U.S.
alone, fenofibrate sales totaled USD 1.3 billion in 2006. In 2007, the fibrate
segment is estimated to increase around 14% over 2006 with estimated gross
sales of USD 1.6 billion. 

Patrick Fourteau, Chief Executive Officer of Sciele Pharma, said, “We are
enthusiastic about introducing LCP's Fenoglide in 40-milligram and
120-milligram dosage strengths. We expect the launch of   Fenoglide, the lowest
dose fenofibrate available to patients, will enable us to increase our share of
the fenofibrate market, which is one of the fastest growing areas of the
cardiovascular market.” 

According to the agreement with Sciele Pharma, LCP will receive tiered royalty
payments on product sales and may also receive milestone payments of up to USD
8 million when certain sales targets are met. 

The launch of Fenoglide demonstrates one of LCP's key strengths; the short time
span from idea to commercialization thanks to the proprietary MeltDose
technology and strong research and development capabilities.  FenoGlide was
developed from pre-clinical trials to FDA approval for sale in the U.S. within
five years as compared with a traditional drug development time of around 8-11
years. 

About LifeCycle Pharma A/S (“LCP”)
LCP is an emerging specialty pharmaceuticals company that, through innovative
technologies, is able to rapidly develop a portfolio of differentiated products
to meet the unique needs of key therapeutic markets and patient populations.
This includes products for immunosuppression, specifically organ
transplantation, and to combat certain cardiovascular diseases.  By using its
unique and patented delivery technology, MeltDose, LCP is able to develop drugs
with enhanced absorption and thereby increased bioavailability. The company has
one product ready for US commercialization, seven clinical development programs
covering five product candidates and three product candidates in preclinical
development. LCP is listed on the OMX Nordic Exchange Copenhagen under the
trading symbol (OMX: LCP). For further information, please visit
www.lcpharma.com. 

For further information please contact:

LifeCycle Pharma A/S
Flemming Ørnskov, MD
President and CEO  
+45 24 20 03 68; fo@lcpharma.com